Incyte Co. (INCY) EVP Vijay K. Iyengar Sells 606 Shares

Incyte Co. (NASDAQ:INCY) EVP Vijay K. Iyengar sold 606 shares of Incyte stock in a transaction dated Monday, July 9th. The shares were sold at an average price of $71.34, for a total transaction of $43,232.04. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ INCY traded up $0.10 during midday trading on Wednesday, hitting $70.28. The stock had a trading volume of 1,418,600 shares, compared to its average volume of 2,196,317. The company has a market cap of $15.18 billion, a PE ratio of 108.95 and a beta of 0.74. Incyte Co. has a 52 week low of $60.22 and a 52 week high of $140.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.84 and a current ratio of 3.86.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, May 1st. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.09) by $0.08. The firm had revenue of $382.28 million for the quarter, compared to the consensus estimate of $384.03 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 0.74%. The business’s revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.14 earnings per share. analysts forecast that Incyte Co. will post 0.41 earnings per share for the current fiscal year.

INCY has been the topic of a number of research reports. SunTrust Banks reaffirmed a “buy” rating and set a $80.00 target price on shares of Incyte in a research note on Friday, April 6th. UBS Group raised shares of Incyte from a “neutral” rating to a “buy” rating and set a $76.00 price objective on the stock in a research note on Thursday, April 12th. Zacks Investment Research raised shares of Incyte from a “hold” rating to a “buy” rating and set a $79.00 price objective on the stock in a research note on Wednesday, April 18th. Evercore ISI raised shares of Incyte from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $60.23 to $140.11 in a research note on Monday, June 11th. Finally, Barclays dropped their price objective on shares of Incyte from $165.00 to $135.00 and set an “overweight” rating on the stock in a research note on Thursday, April 5th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $106.27.

Several hedge funds and other institutional investors have recently modified their holdings of INCY. Nomura Asset Management Co. Ltd. lifted its stake in shares of Incyte by 3.2% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 41,158 shares of the biopharmaceutical company’s stock worth $3,898,000 after buying an additional 1,260 shares in the last quarter. Clearbridge Investments LLC lifted its stake in shares of Incyte by 47.5% in the fourth quarter. Clearbridge Investments LLC now owns 84,661 shares of the biopharmaceutical company’s stock worth $8,018,000 after buying an additional 27,249 shares in the last quarter. Guggenheim Capital LLC lifted its stake in shares of Incyte by 16.9% in the fourth quarter. Guggenheim Capital LLC now owns 735,510 shares of the biopharmaceutical company’s stock worth $69,659,000 after buying an additional 106,468 shares in the last quarter. Two Sigma Advisers LP lifted its stake in shares of Incyte by 10.5% in the fourth quarter. Two Sigma Advisers LP now owns 990,182 shares of the biopharmaceutical company’s stock worth $93,780,000 after buying an additional 94,373 shares in the last quarter. Finally, Two Sigma Investments LP lifted its stake in shares of Incyte by 143.1% in the fourth quarter. Two Sigma Investments LP now owns 729,107 shares of the biopharmaceutical company’s stock worth $69,054,000 after buying an additional 429,181 shares in the last quarter. Hedge funds and other institutional investors own 92.01% of the company’s stock.

About Incyte

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.

Insider Buying and Selling by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply